Variagenics Inc., of Cambridge, Mass., named Jay Mohr vice president, business development and marketing and John Frey senior director, regulatory affairs and clinical informatics

MPM Capital, of Cambridge, Mass., added Carl Weissman as venture partner and Kazumi Shiosaki as entrepreneur in residence...Neose Technologies Inc., of Horsham, Pa., appointed George Vergis vice president, business and commercial development, and Matt Kremer senior director, corporate communications

Phylos Inc., of Lexington, Mass., appointed Michael Furlong senior director, business development...Targeted Genetics Corp., of Seattle, appointed Todd Simpson vice president, finance and administration, and chief financial officer

Also, it promoted William Mikrut and added Terry Murdock, both as vice president, clinical operations...Inspire Pharmaceuticals Inc., of Durham, N.C., appointed Lisa LaVange president of biostatistics and data management and Amy Schaberg senior director of clinical research

and promoted Sergio Garcia-Rodriguez to vice president, legal, general counsel and assistant secretary...Silicon Genetics Inc., of Redwood City, Calif., added Deepak Thakkar as senior director of marketing

and Mark Knowles as senior director, biostatistics

and added Peter Cheung as senior scientist in pharmaceutical discovery...and Mark Knowles as senior director, biostatistics

Elitra Pharmaceuticals Inc., of San Diego, appointed Martin Rosenberg to its board and scientific advisory board and Philip Youngman vice president of discovery biology...Genentech Inc., of South San Francisco, appointed Andrew Chan senior director of immunology in its research department

Also, it hired James Aswell as senior director, diagnostics...and added Christoph Adams as senior vice president, business development

and named Lorella Donato senior director of the ligand services group at its St. Laurent site

and Manfred Scholz senior director, business development...Also, it added Catherine Kara as senior intellectual property counsel and both Brian Stalter and Douglas Haeuber as assistant general counsel

Pamela Hay senior vice president, corporate development and strategic opportunities...Albert Edge vice president of discovery and preclinical research...GenOdyssee, of Les Ulis, France, appointed Jean Maral vice president, senior director of preclinical and clinical affairs

FeRx Inc., of San Diego, added Richard Keatinge as vice president of corporate development and Kenneth Norton as senior director of pharmaceutical development...Also, it named Todd Myers chief financial officer and promoted Scott Rudge to vice president of operations and site director of its Colorado laboratories

Beckman Coulter Inc., of Fullerton, Calif., formed three divisions and named a president of each...ImaRx Therapeutics Inc., of Tucson, Ariz., added Nina Ossanna as senior director of business...Origenix Technologies Inc., of Montreal, elected Michael Atkin and Barry Markowsky to its board

Inspire Pharmaceuticals Inc., of Durham, N.C., added Mary Bennett as vice president, operations and communications and Mark Montgomery as senior director, intellectual property/legal...Limber is president and CEO of Aclara BioSciences Inc., of Mountain View, Calif

AtheroGenics Inc., of Atlanta, promoted David Edwards to senior director of toxicology and early development, Bruce Johnson to senior director of developmental chemistry, and Felicia Ford-Rice to director of quality assurance and compliance

Avidex Ltd., of Oxford, UK, appointed Peter Doyle and Alan Rosenthal nonexecutive directors...and Premchandran Ramiya director of process research and development

Rigel Pharmaceuticals Inc., of San Francisco, added Gregory Wagner as senior director of pharmacology and preclinical development...ZymoGenetics Inc., of Seattle, appointed James Johnson chief financial officer, Shinko Campos senior vice president and chief business and operations officer, and Charles Hart senior director, corporate communications and investor relations

Exelixis Inc., of South San Francisco, added Peter Lamb as senior director of molecular pharmacology and structural biology, Kirk McMillan as director of new lead discovery, John Nuss as senior director of chemistry, and Yifan Zhai as director of pharmacology